Stanford researchers have developed a genome engineering platform for generating genetically precise human cellular models of Lowe syndrome, a rare inherited disorder frequently associated with severe ocular complications, including early-onset glaucoma.
Stanford researchers have developed a next-generation programmable transcriptional activation platform, TIGRa, that addresses key limitations of CRISPRa technologies, including large size, limited multiplexing capacity, and delivery constraints.
Stanford researchers have developed novel AsCas12a-expressing mouse models for simultaneous editing of multiple genomic loci in vivo with unique targeting capabilities relative to traditional Cas9 models, enabling the rapid creation of complex genotypes in somatic cells and ca
Stanford researchers have developed a novel CRISPR-based method, Oligo-LiveFISH, for generating large-scale pools of synthetic RNA oligos that enable multiplexed targeting, imaging, and manipulation of genomic regions in living cells.
Stanford scientists have developed a new DNA-based technology that allows therapeutic genes to be maintained in human cells for extended periods without altering the cell's chromosomes.
Stanford scientists have developed a gene integration system that uses human-derived helicases paired with CRISPR technology to enable precise insertion of long DNA sequences at targeted genomic locations.
Type 1 regulatory T cells (Tr1s) are an inducible subtype of regulatory T cells that can play a beneficial (autoimmune diseases, allergy, hematological malignancies) or detrimental role (some solid tumors and infectious diseases) in human diseases. Tr1 cells.
Stanford researchers have developed novel technology that combines AAVMYO, a muscle cell targeting viral vector, with CRISPR base editors to achieve targeted gene repair, showcasing over 70% correction of hereditary mutations in cardiomyocytes.
Stanford researchers have developed a new methodology called transcript-informed single-cell CRISPR sequencing (TISCC-Seq), for the direct detection and phenotyping of genetic variants in a high-throughput manner.
Researchers at Stanford have developed a CRISPR-based system to degrade viral RNA, with potential applications as both an anti-viral therapeutic and a prophylactic treatment against influenza, SARS-CoV-2, and other viruses.
Polycythemia vera is a rare blood cancer characterized by the hyperproliferation of red blood cells, leading to coagulation events like strokes and heart attacks.
Stanford inventors have developed a method of using CRISPR/Cas9 or similar gene editing technologies to genetically edit an individual's own myeloid cells for specific gene targets, which are critical to wound repair, and applying these edited cells in a hydrogel to promote ra